In the claims:

For the Examiner's convenience, Applicants present all pending claims with status indicators in compliance with the practice guidelines for making amendments under 37 C.F.R. §1.121(c)(1).

Please cancel claims 6-9 and 12 without prejudice to pursue the subject matter of these claims in a related application in the future.

Additionally, please amend claims 1-5, 10-11 and 28 and add new claims 39-43 as follows.

1. (Currently Amended) A composition comprising ~~a culture of~~ isolated human replicating ~~macrophages~~ Kupffer cells, wherein the replicating Kupffer cells
(i) express CD68, and
(ii) do not express TGFβ,
~~at least some of the macrophages have undergone cell division during culture *in vitro*~~
but not comprising Kupffer cells that do not express CD68 and that express TGFβ.

2. (Currently Amended) The composition of claim 1 wherein said replicating ~~macrophages~~ Kupffer cells have undergone cell division during culture *in vitro* for at least one month.

3. (Currently Amended) The composition of claim 1 wherein said replicating ~~macrophages~~ Kupffer cells have undergone cell division during culture *in vitro* for at least four months.

4. (Currently Amended) The composition of claim 1 wherein said replicating ~~macrophages~~ Kupffer cells are phagocytic.

5. (Currently Amended) The composition of claim 1 wherein said replicating ~~macrophages~~ Kupffer cells stain positive for non-specific esterase and acid-phosphatase.

6 to 9. (Cancel)

10. (Currently Amended) The composition of claim 1 wherein said replicating ~~macrophages~~ Kupffer cells are non-transformed.

11. (Currently Amended) The composition of claim 1 wherein said replicating ~~macrophages~~ Kupffer cells are from a tissue source other than a tumor.

12. (Cancel)

13. (Withdrawn) A method of culturing macrophages in vitro such that at least some of the macrophages have undergone cell division during culture, said method comprising growing the cells in basal culture medium comprising inorganic salts, amino acids, vitamins, at least one carbohydrate or metabolic product thereof and further comprising animal serum and IL-1 or IL-2.

14. (Withdrawn) The method of claim 13 wherein said culture medium further comprises dimethyl sulphoxide and hydrocortisone.

15. (Withdrawn) The method of claim 13 wherein said culture medium further comprises heparin.

16. (Withdrawn) The method of claim 13 wherein said animal serum is fetal calf serum.

17. (Withdrawn) The method of claim 13 wherein said culture medium comprises IL-2.

18. (Withdrawn) The method of claim 13 wherein said macrophages are human macrophages.

19. (Withdrawn) The method of claim 13 wherein said macrophages are Kupffer cells.

20. (Withdrawn) The method of claim 19 wherein said Kupffer cells are isolated from human liver by needle biopsy.

21. (Withdrawn) The method of claim 19 wherein said Kupffer cells are isolated from liver of an individual suffering from a liver viral infection.

22. (Withdrawn) The method of claim 21 wherein said Kupffer cells are not virally infected.

23. (Withdrawn) The method of claim 13 wherein said macrophages continue to replicate for at least one month.

24. (Withdrawn) The method of claim 13 wherein said macrophages continue to replicate for at least four months.

25. (Withdrawn) The method of claim 13 wherein said replicating macrophages are non-transformed.

26. (Withdrawn) The method of claim 13 wherein said macrophages are from a tissue source other than a tumor.

27. (Withdrawn) The method of claim 13 wherein said macrophages are from a non-embryonic animal.

28. (Currently Amended) A composition comprising the isolated human replicating Kupffer cells of claim 1, wherein the composition is prepared by ~~the method of claim 13~~ growing the Kupffer cells in macrophage cell growth medium comprising RPMI-1640 supplemented with fetal calf serum, Hepatozyme-sfm, aminochrome-II basal medium, L-Glutamine, hydrocortisone, sodium pyruvate, dimethyl sulphoxide, heparin, endothelial cell growth supplement and recombinant interleukin-2.

29. (Withdrawn) A method of enhancing or extending immune or organ function in an individual suffering from a deficiency relating to a reduced number of functional macrophages in a tissue or organ, said method comprising administering a therapeutically effective amount of the macrophages of claim 1.

30. (Withdrawn) The method of claim 29 wherein said individual is a human.

31. (Withdrawn) The method of claim 29 wherein said organ is liver.

32. (Withdrawn) The method of claim 29 wherein said macrophages are Kupffer cells.

33. (Withdrawn) The method of claim 29 wherein said deficiency is due to hepatitis C virus infection.

34. (Withdrawn) A method of enhancing or extending immune or organ function in an individual suffering from a deficiency relating to a reduced number of functional macrophages in a tissue or organ, said method comprising administering a therapeutically effective amount of the macrophages of claim 28.

35. (Withdrawn) The method of claim 34 wherein said individual is a human.

36. (Withdrawn) The method of claim 34 wherein said organ is liver.

37. (Withdrawn) The method of claim 34 wherein said macrophages are Kupffer cells.

38. (Withdrawn) The method of claim 34 wherein said deficiency is due to hepatitis C virus infection.

39. (New) The composition of claim 1, wherein the isolated human replicating Kupffer cells are negative for any one or more of factor VIII R-Ag, EN-4, PAL-E, ATPases and alkaline phosphatase.

40. (New) The composition of claim 1, wherein the isolated human replicating Kupffer cells are positive for any one or more of TPA-I, 5'nucleotidase and Ac-LDL.

41. (New) The composition of claim 1, wherein the composition does not comprise non-Kupffer cells.

42. (New) The composition of claim 1, wherein the isolated human replicating Kupffer cells are clonally isolated.

43. (New) The composition of claim 1, wherein the isolated human replicating Kupffer cells have undergone at least one cell division during culture *in vitro*.